CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).

Qiong QinXiaoqing LiXingmei LiangLili ZengJing WangLinlin SunDiansheng Zhong

Published in: Thoracic cancer (2020)

An osimertinib acquired resistance cell line (H1975 OR) was successfully established. The expression of cell cycle related genes was altered in H1975OR. The expression of CDK4 and the phosphorylation of Rb, the downstream molecule of CDK4/6, was increased in H1975OR cells. The combination of CDK4/6 inhibitor palbociclib and osimertinib could overcome the acquired resistance of osimertinib.

Keyphrases

cell cycle
small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
cell proliferation
poor prognosis
brain metastases
tyrosine kinase
induced apoptosis
binding protein
metastatic breast cancer
long non coding rna
endoplasmic reticulum stress